Alexander Gintsburg, Director of the "Gamalei" Research Center for Epidemiology and Microbiology, announced plans to begin clinical trials for a new cancer vaccine by mid-2025.
Gintsburg explained that the vaccine is currently undergoing preclinical studies on laboratory mice, where it has shown promising results by significantly extending the lifespans of mice with skin cancer—by 2 to 3 times. The vaccine is based on a technology capable of fully eliminating both tumors and metastases.
He emphasized that, if successfully developed, the vaccine could benefit patients with lung cancer, pancreatic cancer, certain types of kidney cancer, as well as melanoma. These cancers are known for their tendency to spread early, making the vaccine a promising option for combating them.
In related news, Gintsburg noted that previous studies on mice with melanoma tumors have yielded encouraging results. After 15 days of vaccination, there was a significant reduction in tumor size, with the vaccinated mice surviving longer than the non-vaccinated ones, which died between days 19 and 22.
Russian Health Minister Mikhail Murashko also stated that preliminary results from the preclinical studies may be available by the end of this year, opening the door for significant scientific progress in cancer treatment.
This ambitious project marks a major step forward in the fight against one of the deadliest diseases, raising hopes that the vaccine could improve the lives of patients around the world.